• Mashup Score: 28

    This Viewpoint discusses the risks to patients and public health posed by the FDA’s politically pressured Emergency Use Authorization (EUA) of chloroquine and hydroxychloroquine for COVID-19 treatment, and proposes principles to follow to ensure new therapies are studied properly and quickly to…

    Tweet Tweets with this article
    • The recent issuance of the #chloroquine/#hydroxychloroquine #EmergencyUseAuthorization for #COVID19, in the midst of political pressure and with scant and conflicting supporting evidence, should be of serious concern https://t.co/IHxE5BbzsU #Coronavirus

  • Mashup Score: 3

    Twitter debate: Join us on Thursday 16 April at 5pm (BST) for a twitter chat discussing the wider health impacts of the covid-19 pandemic. Join the debate using the hashtag […]More…

    Tweet Tweets with this article
    • The last question for tonight: Q6: What do you think will be the most important lessons we learn from the pandemic? Join in at #BMJDebate and mark your response as A6 https://t.co/3nowNZfiPj

  • Mashup Score: 0

    Results of the phase 3 INTERCEPT trial showed that AXS-07, an oral agent for acute migraine treatment, was significantly more effective at preventing pain progression than placebo and eliminated migraine pain in approximately one-third of patients within 2 hours of dosing, according to a press release from the manufacturer. AXS-07 (MoSEIC meloxicam, rizatriptan; Axsome Therapeutics) also

    Tweet Tweets with this article
    • AXS-07 effective against #migraine pain in phase 3 INTERCEPT trial https://t.co/7MPglUqpWu https://t.co/pyag59YCXf

  • Mashup Score: 0

    President Donald J. Trump recently signed the $2 trillion Coronavirus Aid, Relief and Economic Security Act into law. However, the question remains whether the legislation will be enough to save everyone the medical community. Thelaw, known as the CARES Act, contains multiple provisions to lessen the economic impact of COVID-19 on the medical community and help medical professionals continue to

    Tweet Tweets with this article
    • President @realDonaldTrump said that the #CARESAct will provide relief to families, workers & businesses reeling from the impact of #COVID19. Read what @JFincherMD and @clflickmd are saying about it: https://t.co/nGcNyluJyZ #COVID-19 #coronavirus #medtwitter #primarycare #PPE https://t.co/0hST9eEh3Z

  • Mashup Score: 0

    Among military personnel, post-deployment pulmonary evaluation should target asthma and airway hyperactivity as well as include upper airway disorder testing, according to a prospective study published in Chest.“Understanding that symptoms may be multifactorial in nature and not necessarily related to deployment exposures, patients should be first evaluated for evidence of asthma, airway

    Tweet Tweets with this article
    • Asthma, airway hyperactivity, upper airway disorder should be tested post-deployment https://t.co/775EjCCCse

    • Asthma, airway hyperactivity, upper airway disorder should be tested post-deployment https://t.co/AHorOGjUPt

  • Mashup Score: 7

    Twitter debate: Join us on Thursday 16 April at 5pm (BST) for a twitter chat discussing the wider health impacts of the covid-19 pandemic. Join the debate using the hashtag […]More…

    Tweet Tweets with this article
    • Moving on to Q4: Do you see any positive sides to the rapid changes the pandemic has brought about? Join in at #BMJDebate and mark your response as A4 https://t.co/7hOq5TjoPL